

Xyntha®, Xyntha Solofuse® (antihemophilic factor [recombinant]) – New indication

- On August 13, 2020, the <u>FDA approved</u> Wyeth's <u>Xyntha (antihemophilic factor [recombinant])</u> and <u>Xyntha Solofuse (antihemophilic factor [recombinant])</u> for use in adults and children with hemophilia A (congenital factor VIII deficiency) for routine prophylaxis to reduce the frequency of bleeding episodes.
- Xyntha is also approved for use in adults and children with hemophilia A (congenital factor VIII
 deficiency) for on-demand treatment and control of bleeding episodes and perioperative
 management.
- The approval of Xyntha for the new indication was based on 102 patients receiving Xyntha for routine prophylaxis, for comparison of annualized bleeding rate (ABR) to on-demand treatment alone as a part of 2 completed studies.
 - In patients ≥12 years, 42 (45%) reported no bleeding while on routine prophylaxis. The mean ABR for patients during routine prophylaxis was 88% lower than the mean ABR for patients during on-demand treatment.
 - In patients <12 years, 4 subjects (50%) reported no bleeding while on routine prophylaxis.
 The mean ABR for patients during routine prophylaxis was 97% lower than the mean ABR for patients during on-demand treatment.
- The recommended starting dose of Xyntha for the treatment of routine prophylaxis in adults and adolescents (≥ 12 years) is 30 IU/kg intravenously (IV) administered 3 times weekly.
- The recommended starting dose of Xyntha for the treatment of routine prophylaxis in children (< 12 years) is 25 IU/kg IV administered every other day. More frequent or higher doses may be required in children <12 years of age to account for the higher clearance in this age group.
- The dosing regimen (dose or frequency) should be adjusted based on the patient's clinical response.
 - Refer to the Xyntha drug label for dosing for all its other indications.



optumrx.com

OptumRx® specializes in the delivery, clinical management and affordability of prescription medications and consumer health products. We are an Optum® company — a leading provider of integrated health services. Learn more at **optum.com**.

All Optum® trademarks and logos are owned by Optum, Inc. All other brand or product names are trademarks or registered marks of their respective owners.

This document contains information that is considered proprietary to OptumRx and should not be reproduced without the express written consent of OptumRx.

 $\mbox{RxNews}^{\tiny{\textcircled{\tiny{\scriptsize 0}}}}$ is published by the OptumRx Clinical Services Department.

©2020 Optum, Inc. All rights reserved.